An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism
The Journal of Clinical Endocrinology & Metabolism · 13.08.2024 · 109 (9) · 2199-2209
DOI: 10.1210/clinem/dgae121 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 06.03.2024. Verfasst von Istvan Takacs und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Oncology, Semmelweis University, 1088 Budapest, Hungary. Hauptthemen laut MEDLINE: Hypoparathyroidism, Receptor, Parathyroid Hormone, Type 1. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Amolyt Pharma, France.
Abstract (Originalsprache)
Context
Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP).
Objective
To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients.
Design
Open-label, phase 2 study.
Participants
Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12 and C2, n = 16).
Intervention
Following an optimization period, daily subcutaneous injections of eneboparatide were administered for 3 months at a 20 µg/day (C1) or 10 µg/day (C2) starting dose. Conventional therapy was progressively removed, and eneboparatide could be titrated up to 60 µg (C1) or 80 µg (C2). Main outcomes Proportion of patients achieving independence from conventional therapy, albumin-adjusted serum calcium (ADsCa), 24-h urine calcium (uCa), serum bone turnover markers (serum carboxy-terminal telopeptide of type I collagen and procollagen 1 intact N-terminal propeptide), bone mineral density (BMD), and adverse events (AEs).
Results
After 3 months, ≥ 88% of patients achieved independence from conventional therapy while mean ADsCa was maintained within target range (7.8-9 mg/dL). Eneboparatide induced a rapid and sustained reduction of mean 24-hour uCa, even among patients with hypercalciuria. Bone turnover markers slightly increased, and BMD remained unchanged, consistent with progressive resumption of physiologic bone turnover. Eneboparatide was well tolerated with no serious AEs.
Conclusion
Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Oncology, Semmelweis University, 1088 Budapest, Hungary.
- Department of Endocrinology, Pecsi Tudomanyegyetem, 7623 Pecs, Hungary.
- Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario A Coruña, 15006 Coruña, Spain.
- Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Univ…
- Department of Nephrology and Clinical Immunology, Centre Hospitalier Universitaire Nantes-Université de Nantes, 44093 Nantes, France.
- Department of Endocrinology and Nutrition, Hospital Universitario Reina Sofía, 14004 Cordoba, Spain.
ORCID-Profile: Istvan Takacs, Emese Mezosi, Alfonso Soto, Peter Kamenický, Lucile Figueres, Maria Angeles Galvez Moreno, Sandrine Lemoine, Francoise Borson-Chazot, Ismael Capel, Taha Ouldrouis, Nadège Lucas, Soraya Allas, Mark Sumeray, Michel Ovize, Michael Mannstadt
Förderung
- Amolyt Pharma, France
Zitieren
APA
Takacs, I., Mezosi, E., Soto, A., Kamenický, P., Figueres, L., Galvez Moreno, M. A., Lemoine, S., Borson-Chazot, F., Capel, I., Ouldrouis, T., Lucas, N., Allas, S., Sumeray, M., Ovize, M., & Mannstadt, M. (2024). An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 109(9), 2199-2209. https://doi.org/10.1210/clinem/dgae121
Vancouver
Takacs I, Mezosi E, Soto A, Kamenický P, Figueres L, Galvez Moreno MA, et al. An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 2024;109(9):2199-2209. doi:10.1210/clinem/dgae121
BibTeX
@article{Takacs2024,
author = {Takacs, Istvan and Mezosi, Emese and Soto, Alfonso and Kamenický, Peter and Figueres, Lucile and Galvez Moreno, Maria Angeles and Lemoine, Sandrine and Borson-Chazot, Francoise and Capel, Ismael and Ouldrouis, Taha and Lucas, Nadège and Allas, Soraya and Sumeray, Mark and Ovize, Michel and Mannstadt, Michael},
title = {An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {9},
pages = {2199--2209},
doi = {10.1210/clinem/dgae121}
}
EUVIMED